Journal article
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Abstract
PURPOSE: Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody-drug conjugates (ADC) providing targeted drug delivery have shown antitumor activity in this setting. AGS15E is an investigational ADC that delivers the cytotoxic drug monomethyl auristatin E to cells expressing SLITRK6, a UC-associated antigen.
PATIENTS AND METHODS: This was a multicenter, single-arm, phase I …
Authors
Petrylak DP; Eigl BJ; George S; Heath EI; Hotte SJ; Chism DD; Nabell LM; Picus J; Cheng SY; Appleman LJ
Journal
Clinical Cancer Research, Vol. 30, No. 1, pp. of1–of11
Publisher
American Association for Cancer Research (AACR)
Publication Date
January 5, 2024
DOI
10.1158/1078-0432.ccr-22-3627
ISSN
1078-0432